Unitron Medx
ActiveSummary
Unitron Medx has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €7,453 and a net result of -€3,587. Equity is shrinking by about 3% per year across the filed financial years. Its solvency ranks better than 19% of 146 sector peers (NACE 26, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Unitron Medx
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, Artikel 2” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Met of zonder beperking duur, bestuursorgaan” (deed in Dutch)
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
- Share issue ruleHow and by whom new shares can be issued.
- “Ten minste vijftien dagen vanaf openstelling intekening, eerst aan bestaande aandeelhouders naar evenredigheid van bezit” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Second Thursday of May
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Statutenwijziging, beslissing algemene vergadering” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- One provision in the deed